Early Phase 1 Stomach Cancer Trial, Recruiting NCT06828588 Sponsor: Vanderbilt-Ingram Cancer Center Condition: Stomach Cancer
Back to Stomach Cancer

Early Phase 1 Stomach Cancer Trial, Recruiting

NCT06828588
Recruiting Early Phase 1

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You must be 18 years of age or older.
  • You have cancer that cannot be removed by surgery and has either spread to nearby areas or to other parts of the body, and your doctor has recommended a HER2-targeted treatment as a standard option for your cancer type.
  • You are either about to start HER2-targeted therapy, or you have recently started it and have received no more than 6 rounds (cycles) of treatment so far.
  • A previous tissue sample (biopsy) has shown that your cancer tests positive for a protein called HER2, or is "HER2-low," based on standard lab tests or a blood-based test done as part of your normal cancer care.
  • You have areas of cancer that can be measured on standard scans (such as CT, PET, or MRI), and at least one of those measurable areas is outside the liver.
  • Your doctor estimates you have a life expectancy of at least 6 months.
  • You may still be eligible even if you have cancer that has spread to the brain.

Who may not be able to join:

  • All of your measurable cancer spots are located only in the liver, with none elsewhere.
  • You are unable or unwilling to follow the study procedures as required.
  • You have a known allergy or sensitivity to any ingredient in the imaging drug used in this trial, called [68Ga]Ga-ABY-025.
  • You are currently pregnant or breastfeeding.
  • Your cancer tests negative for HER2 and there is no FDA-approved reason to use HER2-targeted therapy for your cancer type.
  • You are unable to lie still and flat for 30 minutes during a scan session.
  • You have other medical or mental health conditions that your doctor believes would prevent you from safely or successfully taking part in the study.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
Early Phase 1 studies are small, early exploratory studies that come before the main Phase 1 to 3 testing, so a standard phase success rate does not apply.

Contact this trial

Phone: +1 (615)421-4370

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Early Phase 1
Sponsor
Vanderbilt-Ingram Cancer Center
Registry
ClinicalTrials.gov
Start date
16 April 2026
Est. completion
1 December 2027

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Determine safety of [68Ga]Ga-ABY-025 PET by assessing for adverse events following the injection and PET imaging.

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov